CRANBURY, N.J.--(BUSINESS WIRE)--Physicians’ Education Resource® (PER®), the nation’s leading resource for oncology and hematology continuing medical education (CME), will host the Third Annual International Congress on Immunotherapies in Cancer®: Focus on Practice-Changing Application. The event will take place Saturday, Dec. 15, at InterContinental New York Times Square in New York City. The program will be co-chaired by Antoni Ribas, M.D., Ph.D., professor of medicine, surgery, molecular and medical pharmacology at UCLA, director of the tumor immunology program at Jonsson Comprehensive Cancer Center (JCCC), and chair of the SWOG melanoma committee, and Naiyer A. Rizvi, M.D., professor of medicine in the division of hematology and oncology, director of thoracic oncology and immunotherapeutics, and the Price chair in clinical translational research at Columbia University Irving Medical Center.
“The emergence of immunotherapies and their roles in the treatment of cancer have transformed the way clinicians manage their patients with different forms of malignancies,” said Phil Talamo, president of PER®. “We are so thrilled to present this international congress once again that will update health care professionals on relevant and exciting areas of drug development in oncology.”
Faculty for the educational activity will include the following experts:
- Joaquim Bellmunt, M.D., Ph.D., associate professor of medicine, Harvard Medical School, and director, Bladder Cancer Center, Dana-Farber Cancer Institute.
- Julie Brahmer, M.D., director, thoracic oncology program, and professor of oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medicine.
- Ezra Cohen, M.D., FRCPSC, FASCO, professor of medicine, University of California, San Diego; co-director, San Diego Center for Precision Immunotherapy; and associate director, translational science, and leader, solid tumor therapeutics research program, UC San Diego Moores Cancer Center.
- Elaine R. Mardis, Ph.D., Nationwide Foundation endowed chair of genomic medicine and professor of pediatrics, the Ohio State University College of Medicine, and co-executive director, Institute for Genomic Medicine, Nationwide Children’s Hospital.
- Marcela V. Maus, M.D., Ph.D., assistant professor of medicine, Harvard Medical School, and director, cellular immunotherapy, Cancer Center, Massachusetts General Hospital.
- David F. McDermott, M.D., professor of medicine, Harvard Medical School, and staff physician, hematology and oncology, and director, biologic therapy and cutaneous oncology programs, Beth Israel Deaconess Medical Center.
- Drew M. Pardoll M.D., Ph.D., Abeloff professor of oncology, medicine, pathology and molecular biology and genetics, Johns Hopkins University School of Medicine; director, Bloomberg-Kimmel Institute for Cancer Immunotherapy; and co-director, cancer immunology program, Sidney Kimmel Comprehensive Cancer Center.
- Michael A. Postow, M.D., board-certified medical oncologist, Memorial Sloan Kettering Cancer Center.
- Jeffrey S. Weber, M.D., Ph.D., professor of medicine, New York University Langone Health, and deputy director, Perlmutter Cancer Center.
The International Congress on Immunotherapies in Cancer® is an intensive and interactive 1-day program that will provide oncologists, nurses and pharmacists with a comprehensive review of the key data sets that are most relevant to the application of these novel strategies for the clinician who manages some of the most difficult-to-treat forms of cancer. The program will also feature two Medical Crossfire® sessions throughout the evening and will focus on the practical application of recent clinical trial results that have shaped current and evolving clinical management, evolving biomarker information, the latest basic science findings and the most highly anticipated clinical trials in the field.
For more information and to register, click here.
About Physicians’ Education Resource® (PER®)
Since 1995, PER® has been dedicated to advancing cancer care through professional education and now furthers patient care and treatment strategies on a wide variety of chronic illnesses and diseases. In 2016, PER® initiated CME programming in the cardiovascular and endocrinology areas and continues to grow its therapeutic reach outside of oncology. While continuing to expand into topics outside of oncology, PER® remains the leading provider of live, online and print CME activities related to oncology and hematology. The high-quality, evidence-based activities feature leading distinguished experts who focus on the application of practice-changing advances. By the end of 2018, PER® will have developed and implemented 21 historic annual legacy conferences in the United States and Europe, along with many renowned online learning formats. PER® is accredited by the Accreditation Council for Continuing Medical Education and the California Board of Registered Nursing. PER® is part of the Cranbury, New Jersey-based MJH Associates Inc. family of businesses. Learn more at http://www.gotoper.com and http://www.mjhassoc.com.
